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Summary
 
We studied the impact of various infectious and proinflammatory agents on the induction of
peripheral T cell tolerance. Adoptive transfer of CD8
 
1
 
 T cells from lymphocytic choriomenin-
gitis virus (LCMV) T cell receptor transgenic mice into LCMV antigen transgenic mice ex-
pressing the LCMV glycoprotein epitope (gp) 33–41 under control of a major histocompatibil-
ity complex class I promoter led to efficient induction of peripheral tolerance after a period of
transient activation. If, however, the recipient mice were challenged with viral or bacterial in-
fections or proinflammatory agents (lipopolysaccharide or Poly:IC) early after cell transfer, tol-
erance induction was prevented and instead, CD8
 
1
 
 T cell activation leading to vigorous ex-
pansion and generation of cytolytic activity ensued. This became manifest in significant
immunopathology mainly involving destruction of the splenic architecture and lysis of antigen-
expressing lymphocyte and macrophage populations. Important parameters involved in the ac-
tivation of host-reactive T cells by nonspecific infectious agents included the presence, localiza-
tion, and quantity of the specific transgene-encoded self-antigen; in contrast, CD4
 
1
 
 T cells
were not required. In mice surviving the acute phase, the transferred CD8
 
1
 
 T cells persisted at
high levels in an anergic state; they were unable to generate cytolytic activity in vitro or to
control LCMV infection in vivo. These results impinge on our understanding of the role of in-
fectious agents in graft verus host reactions towards minor histocompatibility antigens.
 
T
 
cell tolerance to self-antigens expressed in the thymus
primarily occurs via clonal deletion of immature thy-
mocytes. In addition, various mechanisms of peripheral T
cell tolerance have been described, which maintain unre-
sponsiveness of clones that are potentially reactive to pe-
ripheral self-antigens, which may be underrepresented in
the thymus. (
 
a
 
) One mechanism, ignorance, is where the
antigen is not encountered by the T cell during its normal
recirculation pathway in sufficient quantity to cause im-
mune reactivity (1, 2). This state of tolerance can be bro-
ken if antigen is introduced into lymphoid tissue, i.e., into
a location where T cells find appropriate qualitative and
quantitative conditions to be activated (3). (
 
b
 
) Another is
anergy, where contact with antigen induces functional un-
responsiveness (4, 5). T cell anergy can be reversed if con-
tinuous contact with the tolerogen is lacking (6), and par-
tial reversion of anergy may also be induced by infectious
agents (7). (
 
c
 
) There is also peripheral clonal deletion where
contact with antigen induces cell death (8–10). This may
be the consequence of a powerful, exhaustive immune re-
sponse (8, 10), but may also only be preceded by a brief pe-
riod of activation, which is of limited functional relevance
(11). Obviously, this form of tolerance is irreversible; it has
been described, however, that proinflammatory agents such
as LPS may interfere with the induction of tolerance and
instead lead to T cell activation under certain conditions
(12–15).
Peripheral deletion of T cells induced by MHC-pre-
sented peptide antigens has been widely studied using T
cells from TCR transgenic mice adoptively transferred into
mice expressing their nominal antigen. Thus, it was shown
that naive H-Y–specific T cells transfused into nude male
hosts largely disappeared after a period of extensive prolif-
eration, leaving behind a small proportion of anergic cells
(9). Similar observations have been made using mice ex-
pressing a transgenic TCR specific for K
 
b
 
 (16) or L
 
d
 
 (17).
Evidence has also been presented that more restricted tis-
sue-specific antigen expression may be sufficient to cause
peripheral T cell deletion (18).
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Surprisingly, even though large numbers of antigen-spe-
cific cytotoxic T cells were transferred and activated in the
experimental systems described above, peripheral deletion
usually occurred without immunopathological consequences.
This is in contrast to the situation encountered during bone
marrow transplantation, when transfusion of large numbers
of lymphocytes into hosts ubiquitously expressing major or
minor histocompatibility antigens that may be recognized
by donor cells frequently leads to activation and severe im-
munopathology resulting in the clinical picture of graft ver-
sus host (GVH)
 
1
 
 disease (19). The factors important for ac-
tivation versus tolerance of host-specific T cells after bone
marrow transplantation have not been characterized in de-
tail. An interesting clinical and experimental observation is,
however, that infections may exacerbate and aggravate
GVH disease (20).
In this study we describe a model system where naive
CD8
 
1
 
 T cells specific for a lymphocytic choriomeningitis
virus (LCMV) peptide were transferred into mice express-
ing this nominal LCMV epitope as a transgene under con-
trol of an ubiquitous promoter; this situation is comparable
to a defined minor histocompatibility antigen difference.
Similar to previous studies, we found that the specific T
cells were deleted after a period of transient activation. If,
however, an inflammatory process was created by viral or
bacterial infections or by the injection of LPS or Poly:IC,
the CD8
 
1
 
 T cells were activated by the transgene-encoded
self-antigen, vigorously expanded, and caused significant
immunopathology similar to a GVH reaction.
 
Materials and Methods
 
Gene Constructions and Transgenic Mice.
 
To generate mice with
ubiquitous expression of an LCMV-derived CTL epitope, we
constructed a hybrid LCMV/H-2K
 
b
 
 transgene. In this construct,
the 5
 
9
 
 part of exon 1 of the genomic K
 
b
 
 gene encoding amino ac-
ids (aa) 1–12 was replaced by a cDNA fragment encoding aa 1–60
of the LCMV glycoprotein (Fig. 1 
 
a
 
). For this, the EcoRI frag-
ment of the genomic K
 
b
 
 gene (provided by Dr. B. Arnold,
Deutsches Krebsforschungszentrum, Heidelberg, Germany) was
cloned into the EcoRI site of pUC 19 (pRIKb10). In this plasmid,
the NruI/XmaIII fragment (encoding aa 1–12 of exon 1 of the
K
 
b
 
 molecule) was replaced by a PCR product encoding aa 1–60 of
the LCMV glycoprotein gene. The PCR product was generated
from the pKOOL plasmid (1) encoding the BamHI fragment of
the LCMV glycoprotein (GP) cDNA. For the PCR reaction 5
 
9
 
(TCGCGAGGATTCTATCCAGTAAAAGGATGG) and 3
 
9
 
(CTGTGGCATGTACGGCCGTAATG) primers were used
which contained Nru1 and XmaIII restriction sites at their 5
 
9
 
 and
3
 
9
 
 ends, respectively. The LCMV GP fragment was inserted such
that the following K
 
b
 
 aa sequence was put out of frame leading to
a premature stop in exon 2 of the K
 
b
 
 gene. The final transgenic
construct was controlled by nucleotide sequencing of the re-
placed region. The transgene was microinjected into fertilized
C57BL/6 oocytes and founder number 8 (official nomenclature:
TgN (LCMVGP33) 224 Zbz; designated H8 in this manuscript)
was used in this study.
C57BL/6 mice were obtained from the Institut für Labor-
tierkunde (University of Zürich, Zürich, Switzerland). The trans-
genic mice expressing a V
 
a
 
2/V
 
b
 
8.2 T cell receptor specific for aa
33–41 of the LCMV glycoprotein 1 in association with H-2 D
 
b
 
(TCR327 mice) on 50% of all CD8
 
1
 
 T cells have been described
previously (21). Perforin-deficient and recombination activating
gene (RAG)1-deficient TCR318 mice (TCR318-Pfp
 
tm
 
 and
TCR318-RAG1
 
tm
 
 mice, respectively) were bred by crossing
mice of line 318 to perforin-deficient (22) or RAG-1–deficient
(23) animals. For preparation of bone marrow chimeras, recipient
mice were exposed to 1,000 centiGrey (cGy) and 24 h later in-
jected intravenously with 10
 
7
 
 untreated bone marrow cells. Mice
were depleted of CD4
 
1
 
 T cells as described (24). All mice were
kept under specific pathogen-free conditions.
 
Infectious and Proinflammatory Agents.
 
LCMV strain WE (LCMV-
WE) was originally obtained from F. Lehmann-Grube (Heinrich-
Pette-Institut fuer Experimentelle Virologie, University of Ham-
burg, Hamburg, Germany) and was propagated on L 929 fibroblast
cells. The LCMV-WE CTL escape variant 8.7 was generated by
injection of TCR318 mice with the parental WE strain (25). Vi-
rus titers in infected organs were determined using a virus plaque
assay on MC57G cells as described previously (26). Vaccinia virus
WR and the recombinant vaccinia viruses expressing the LCMV
nucleoprotein (NP) (obtained from Dr. H.L. Bishop, Institute of
Virology, Oxford University, Oxford, UK) and aa 1–57 of the
LCMV GP (obtained from Dr. Linsey Whitton, Scripps Research
Institute, La Jolla, CA) were grown on BSC 40 cells and plaqued
on the same cells. 
 
Listeria monocytogenes
 
 (originally obtained from
R.V. Blanden, Australian National University, Canberra, Austra-
lia) was kept and prepared as described previously (27). All patho-
gens as well as Poly:IC (Fluka, Chemie Ab, Buchs, Switzerland)
and LPS 
 
Escherichia coli
 
 026:B6 (Chemie Brunschwig AG, Basel,
Switzerland) were injected intravenously.
 
FACS
 
Ò
 
 Analysis.
 
For detection of TCR318 T cells in recipi-
ent mice, spleen cells or PBLs were incubated with FITC-labeled
anti-CD8, PE-labeled anti-V
 
a
 
2, and biotinylated anti-TCR V
 
b
 
8
(all from PharMingen, San Diego, CA) mAb followed by Tri-
color-streptavidin (CALTAG Labs., South San Francisco, CA;
reference 28). For the detection of activation markers, biotiny-
lated anti-CD62 ligand (L), CD44, and CD49d (all from Phar-
Mingen) mAb were used instead of anti-TCR V
 
b
 
8. To analyze
the splenic lymphocyte subsets, spleen cells were stained with
FITC anti-B220, PE anti-CD4 and biotinylated anti-CD8 (all
from PharMingen), followed by Tricolor-streptavidin. Cells were
analyzed on a FACScan
 
Ò
 
 flow cytometer (Becton Dickinson,
Mountain View, CA).
 
Functional CTL Assays.
 
For determination of ex vivo cy-
tolytic activity, effector spleen cell suspensions were prepared.
EL-4 target cells were coated with the LCMV peptides glycopro-
tein epitope (gp) 33–41, np 396–404 (10
 
2
 
6
 
 molar for 2 h), or left
untreated. 
 
51
 
Cr–release assays were performed according to stan-
dard protocols (29) at the indicated effector/target ratios using
5- or 15-h incubation periods. For some experiments, effector cells
were restimulated for 5 d with thioglycolate-induced LCMV-
WE–infected macrophages before the 
 
51
 
Cr–release assay. Con A
blast target cells were obtained by incubating spleen cells of naive
mice at 2 
 
3
 
 10
 
6
 
 cells/ml in IMDM 10% FCS containing 5 
 
m
 
g/ml
Con A. After 3 d of stimulation, the cells were harvested, purified
by a Ficoll gradient, and labeled with 
 
51
 
Cr. Embryonal fibroblast
 
1
 
Abbreviations used in this paper:
 
 aa, amino acids; CFSE, 5,6 carboxyfluorescein
diacetate succinimidyl ester; FDC, follicular dendritic cell; GP, glycoprotein;
GVH, graft versus host; GVHR, GVH reaction; H8 mice, LCMV gp33-
transgenic mice; L, ligand; LCMV, lymphocytic choriomeningitis virus;
NP, nucleoprotein; RAG, recombination activating gene; VSV, vesicular
stomatitis virus. 
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target cells were obtained by culturing single-cell suspensions
from day 14–19 embryos, which were trypsinized after decapita-
tion and removal of the liver. They were seeded into 96-well
plates at a concentration of 2 
 
3
 
 10
 
4
 
 cells per well on the day be-
fore the assay. Then, 10 
 
m
 
l of 
 
51
 
Cr (10 
 
m
 
Ci) were added for 3 h,
the cells were washed three times in the plates, and effector cells
were added at standard effector dilutions. For in vitro T cell pro-
liferation assays, 5 
 
3
 
 10
 
5
 
 responder spleen cells were restimulated
in vitro on 2 
 
3
 
 10
 
5
 
 irradiated C57BL/6 spleen cells pulsed with
LCMV gp 33. Responder cell proliferation was assessed after 48 h
of proliferation of culture by addition of [
 
3
 
H]thymidine (25 
 
m
 
Ci/
well) for the last 12 h of incubation. T cell proliferation in vivo
was assessed in the lymph nodes of recipient mice 40 h after trans-
fer of TCR318 spleen cells labeled with the fluorescent dye 5,6
carboxyfluorescein diacetate succinimidyl ester (CFSE; Molecular
Probes, Eugene, OR). For fluorescence labeling, spleen cells
were incubated at a concentration of 5 
 
3
 
 10
 
6
 
 cells/ml in buffered
saline solution containing 0.5 
 
m
 
molar CFSE for 10 min at 37
 
8
 
C.
 
Histology and Immunohistology.
 
Histological procedures were
performed as described previously (30) using the following pri-
mary antibodies: anti-CD8 (YTS 169; reference 24), anti-CD4
(YTS 191; reference 24), anti-B220 (PharMingen), anti–marginal
metallophils (MMs; metallophilic macrophage 1; Biomedicals,
Augst, Switzerland), and anti–follicular dendritic cells (FDCs; 4C11;
reference 31). Primary rat mAb were revealed by a twofold se-
quential incubation with rabbit anti–rat Ig and rat alkaline phos-
phatase anti–alkaline phosphatase complex (DAKO, Glostrup, Den-
mark) followed by naphthol AS-B1 phosphate and New Fuchsin
as substrate for the color reaction. Peripheral blood and bone
marrow cytology were determined as described previously (32).
 
Results
 
Functional Expression of LCMV gp 33–41 in H8 Mice.
 
Functional expression of LCMV gp 33–41 in H8 mice was
verified in the following experiments. (
 
a
 
) Con A–stimu-
lated T cell blasts from H8 mice were effectively lysed by
spleen cells from C57BL/6 mice that had been infected
with 200 pfu of LCMV-WE 8 d previously (Fig. 1 
 
b
 
). (
 
b
 
)
Spleen cells of H8 mice caused proliferation of LCMV-spe-
cific TCR transgenic responder cells to a similar extent as
spleen cells from C57BL/6 mice exogenously loaded with
the synthetic gp 33 peptide (Fig. 1 
 
c
 
). (
 
c
 
) Embryonal fibro-
blasts of H8 mice were specifically lysed by LCMV-specific
effector cells, albeit to a lesser extent than gp 33–labeled
fibroblasts obtained from C57BL/6 mice (Fig. 1 
 
d
 
). (
 
d
 
)
Analysis of H8 mice crossed to mice transgenic for a gp
33–specific TCR revealed extensive thymic deletion of gp
33–specific CD8
 
1
 
 T cells (data not shown), leading to com-
plete and specific tolerance of gp 33-reactive CTLs. Collec-
tively, these data suggest that the gp 33 epitope was func-
tionally presented by both lymphoid and nonlymphoid cells
in H8 mice.
 
Peripheral Tolerance Induction After Transient Activation of
Transferred gp 33–specific CD8
 
1
 
 T Cells in H8 Mice.
 
To study
the fate of gp 33–reactive CD8
 
1
 
 T cells after exposure to
an environment, where their nominal antigen is widely ex-
pressed both on lymphoid and nonlymphoid cells, we
transfused nonirradiated H8 and littermate control mice
with 5 
 
3
 
 10
 
7
 
 spleen cells from RAG1-deficient TCR
transgenic (TCR318-RAG
 
tm
 
) mice, which had been la-
beled with the fluorescent dye CFSE. 40 h later, CD8
 
1
 
 T
cells of lymph nodes of recipient mice were analyzed by
flow cytometry. Fig. 2 
 
a
 
 shows that in lymph nodes of lit-
termate control mice, one discrete peak of CFSE
 
hi
 
 cells
could be identified. In contrast, analysis of lymph node cells
of H8 mice revealed several peaks of lower intensity (Fig.
2 
 
b
 
), suggesting that the antigen-specific donor T cells had
undergone several rounds of cell division. (Fig. 2 
 
c
 
). Down-
regulation of CD62L and elevated expression of CD44
(Fig. 2 
 
d
 
) on CD8
 
1
 
 T cells further supported the observa-
tion that the TCR318-RAG
 
tm
 
 CFSE
 
lo
 
 population had
been activated after transfer into H8 mice.
Although these phenotypic markers provided evidence
for activation of transgenic CD8
 
1
 
 T cells, further analysis
revealed that this was not of major functional consequence.
Spleen cells of recipient mice did not show gp 33–specific
cytotoxicity in a sensitive 15-h 
 
51
 
Cr–release assay 1, 3, 6, or
8 d after transfer of 5 
 
3
 
 10
 
7
 
 TCR318 spleen cells (Fig. 2 
 
e
 
).
Also, no signs of immunopathology could be demonstrated
by clinical observation, histology (not shown), or lysis of gp
33–expressing recipient lymphocytes (Table 1, experiment
 
A
 
, see below). Finally, cell division appeared limited as
TCR318 CD8
 
1
 
 T cells remained undetectable in FACS
 
Ò
 
analysis of recipient spleen cells using TCR V
 
a
 
2/V
 
b
 
8–spe-
cific antibodies (Fig. 2 
 
f
 
, days 1–12).
To evaluate the further fate of the transferred TCR318
CD8
 
1
 
 T cells, the recipient mice were infected with 200
Figure 1. Functional presentation of gp 33–41 in H8 mice. (a) The
transgene construct: a fragment of the LCMV glycoprotein sequence in-
cluding the gp 33–41 CTL epitope was cloned into the genomic se-
quence of H-2Kb. (b and c) Functional expression of gp 33–41 in periph-
eral lymphoid tissue. (b) Spleen cells from day 8 immune C57BL/6 mice
were used as effector cells against Con A blast target cells obtained from
H8 or C57BL/6 mice; as a control, C57BL/6 Con A blast target cells
pulsed with gp 33–41 were used. Spontaneous release was ,28%. (c) H8-,
C57BL/6-, and gp 33–41-pulsed C57BL/6 spleen cells were used as stim-
ulators for TCR318 responder spleen cells in a [3H]thymidin incorpora-
tion assay. (d) Functional gp 33 expression on fibroblasts. Embryonal fi-
broblasts from H8 and C57BL/6 mice were left unmanipulated or were
pulsed with gp 33–41 and used as targets for effector cells obtained from
LCMV-WE–infected C57BL/6 mice in a 5-h 51Cr–release assay; sponta-
neous release was ,30%.766 Infections Interfere with T Cell Tolerance
PFU LCMV-WE 12 d after transfer. Fig. 2 f shows that in-
fection of control mice transfused with as little as 106 spleen
cells (containing z5 3 104 TCR318 CD81 T cells) lead to
vigorous expansion of the transgenic T cells, whereas in H8
mice, even after transfer of 5 3 107 spleen cells, no
TCR318 T cells could be restimulated by the virus infec-
tion. Also, attempts to recover gp 33–reactive CD81 T
cells in vitro by antigen-specific restimulation in the pres-
ence of Con A supernatant were unsuccessful (data not
shown). Thus, it appears likely that, as previously described
in similar experimental systems, transfer of TCR318 T cells
into mice widely expressing their nominal antigen leads to
clonal deletion and/or induction of anergy after a period of
transient activation. Experiments using bone marrow chi-
Figure 2. Peripheral tolerance induction after transient activation of transferred gp 33–specific CD81 T cells in H8 mice. (a–d) H8 and littermate con-
tol mice were transfused with 5 3 107 CFSE-labeled spleen cells from RAG1-deficient mice transgenic for a gp 33–41-specific T cell receptor
(TCR3RAG). 40 h after transfer, mesenteric lymph node cells were analyzed by flow cytometry. CFSE staining of CD81 cells from littermate (B6; a) or
H8 recipient mice (b) is shown. CFSE1 CD81 lymph node cells from both recipients were compared for their expression of CD62L (c) and CD44 (d). (e)
Spleen cells of H8 mice transfused with 5 3 107 spleen cells from TCR318 mice were analyzed at the indicated times after transfer for gp 33–specific cy-
totoxicity on EL-4 target cells in a 15-h 51Cr–release assay. Spleen cells from C57BL/6 mice immunized with LCMV-WE 50 d earlier (B6 memo) were
used as control. Spontaneous release was ,25%. ( f ) H8 mice and littermate control (B6) mice were transfused with the indicated number of spleen cells
from TCR318 mice. The percentage of CD81 PBLs expressing the transgenic Va and Vb chains was monitored at the indicated time points before and
after challenge infection with 200 PFU LCMV.
Table 1. Splenic Immunopathology Induced by Infectious and Proinflammatory Agents
Experiment Recipient Total spleen cell count Percent CD41 Percent CD81 Percent B2201
A TCR® H8 6 3 107 18 9 53
TCR® littermate 5 3 107 17 10 56
B TCR® H8 LCMV 3 3 106 4.2 21 0.6
TCR® littermate LCMV 9 3 107 18 21 55
C TCR® H8 LCMV 8.7 3 3 107 2.1 12.5 0.75
TCR®H8 vacc 8 3 107 92 2 1 5
TCR®H8 VSV 9 3 106 12 21 1.2
TCR®H8 Listeria 1 3 107 8.6 14.5 2.1
TCR®H8 LPS 2 3 107 14.4 25 10.7
TCR®H8 Poly:IC 5 3 107 0.73 17 2.4
D TCR 3 PKO® H8 LCMV 2 3 107 16 45 1.53
TCR 3 PKO® B6 LCMV 9 3 107 12 13 56
H8 and littermate control mice were transfused with 5 3 107 (A), 106 (B), or 107 (C) spleen cells from TCR318 mice or with 106 spleen cells from
TCR318 mice deficient in perforin (TCR318-Pfptm; D). 1–3 d after transfer, they were injected with 500 mg Poly:IC, 10 mg LPS, 2 3 106 PFU
VSV-Indiana, 2 3 106 PFU vaccinia WR, 200 PFU LCMV-WE, or WE 8.7. 20–35 d later, spleen cells of the recipient mice were counted and the
relative percentage of lymphocyte subpopulations was determined by flow cytometric analysis. Data are the mean of two to six mice per group and
were obtained in several separate experiments.767 Ehl et al.
meras revealed that this peripheral tolerance induction was
equally efficient whether the peptide was expressed only on
bone marrow–derived cells or predominantly in nonlym-
phoid tissues (not shown).
Virus Infection Interferes with Tolerance Induction and Causes
CD81 T Cell–mediated Immunopathology. The experiments
described above confirmed the finding that high numbers
of potentially host-reactive cells can be efficiently rendered
tolerant in the periphery without causing damage to host
tissue. To address the question of whether infectious agents
may influence this tolerization process, we infected H8 and
littermate control mice with 200 PFU LCMV-WE 1–3 d
Figure 3. Virus-induced host-specific CD81 T cells mediate GVH-like immunopathology. H8 and littermate control mice were transfused with 106
spleen cells from TCR318 mice and infected with 200 PFU LCMV 1 d later. At different time points after infection, tissue sections of spleen (d35), gut,
and liver (d50, separate experiment) were stained with hematoxilin–eosin (HE) or with Abs of the desired specificity. B220, CD45R1 B cells; CD4,
CD41 T cells (YTS-191); CD8, CD81 T cells (YTS-169); MOMA, marginal metallophilic macrophages; 4C11, FDCs.768 Infections Interfere with T Cell Tolerance
after transfer of 106 TCR318 spleen cells. Although infec-
tion of control mice did not lead to detectable clinical ill-
ness, H8 mice started showing signs of wasting 6–8 d after
infection and between 20–40% (up to 100% if the experi-
ments were done under non–specific pathogen-free condi-
tions) died within 12–15 d after infection. The remaining
mice continued to lose weight and all of them died 3–5 mo
after infection.
Histological examination of the recipient mice 35 d after
infection revealed profound alterations in splenic architec-
ture and cellular composition in H8 mice compared to lit-
termate controls. Macroscopically, the spleen was small and
had a fibrotic appearance, the follicular structure was
largely dissolved and almost all B cells, CD4 cells, FDCs,
and marginal zone macrophages were absent (Fig. 3; Table
1, experiment B). Total spleen cell counts were reduced
20–50-fold and CD81 T cells were the only cell popula-
tion demonstrable at significant numbers; z90% of them
carried the transgenic, gp 33–specific TCR. Kinetic studies
showed that this splenic immunopathology was already
prominent 12 d after infection and persisted for at least 60 d,
which was the latest time point analyzed (Fig. 4). Interest-
ingly, after infection of H8 mice transfused with perforin-
deficient TCR318-Pfptm cells, the elimination of B cells
was as pronounced (Table 1, experiment D) and the histo-
logical alterations similar (not shown), but the outcome was
not lethal.
CD81 T cell infiltrations were also observed in other
target organs of GVH reactions such as liver, gut, and skin
(Fig. 3). Tissue destruction was limited, however, and nei-
ther lead to prolonged elevation of liver enzymes nor to
extensive eczemematous lesions of the skin. Finally, bone
marrow and peripheral blood counts were significantly al-
tered in infected H8 mice compared to negative littermate
controls; bone marrow cellularity was reduced by a factor
of 2–5. Peripheral white cell counts were reduced by a fac-
tor of 5, and red cell counts were similar, but reticulocyte
counts were reduced by a factor of 10 and thrombocyte
counts were reduced twofold. There were no obvious signs
of bleeding, however, and it is unclear whether these signs
of pathology alone can explain the acute deaths.
The clinical course described above showed that LCMV
infection not only interfered with the induction of CD81
T cell tolerance by host tissue, but instead caused severe
immunopathology. Numeric and functional analysis of the
host-specific TCR transgenic CD81 T cells revealed that
this was paralleled by their extensive proliferation (Fig. 5 a)
and the generation of donor-derived (gp 33)–specific cyto-
toxicity (Fig. 5 b) 8 d after infection. The TCR318 T cells
then returned to memory levels in transgene negative con-
trol mice (28), but remained at high levels (up to 90% of all
CD81 T cells) in H8 mice for the observation period of 60 d
(Fig. 5 b).
Anergy of Persisting Host-specific CD81 T Cells in H8
Mice. In the following experiments, the persisting gp 33–
specific CD81 T cells were characterized phenotypically
and functionally. Flow cytometric analysis of spleen cells of
H8 mice 30 d after virus infection revealed an activated
phenotype of the transferred TCR318 CD81 T cells when
compared to littermate controls. The transgenic TCR-a
and -b chains were downregulated about four to fivefold
(Fig. 6, a and b); the cells had increased forward scatter (Fig.
6 c) and expressed higher levels of CD49d (Fig. 6 d), which
has been characterized as a useful marker to discriminate
between acutely activated versus memory cells (28). Note
that host CD81 T cells carrying endogenous TCR chains
had mostly been eliminated (Fig. 6, a and b). In strong con-
trast to these phenotypic signs of activation, functional
analysis revealed little in vivo or in vitro activity of these
cells. Restimulation in vitro with or without addition of
Con A supernatant did not lead to generation of gp 33–
specific cytotoxicity (Fig. 6 e). Similarly, the proliferative
response to gp 33–pulsed spleen stimulator cells was
strongly reduced and could not be recovered by the addi-
tion of Con A supernatant (Fig. 6 f). Finally, antiviral activ-
ity in vivo was ineffective since LCMV persisted in several
organs of H8 mice 35 d after infection, whereas virus was
readily controlled in littermate controls (Fig. 6 g). This was
not due to the generation of CTL escape mutants as
LCMV isolated from H8 mice 35 d after infection was well
recognized by gp 33–stimulated transgenic effector cells in
vitro as assessed by a 51Cr–release assay (data not shown).
Figure 4. Kinetics of splenic im-
munopathology mediated by virus-
induced  host-specific CD81 T
cells. H8 and littermate control
(B6) mice were transfused with
106 spleen cells from TCR318
mice and infected with 200 PFU
LCMV 1 d later. At the indi-
cated time points after transfer,
mice were killed and the absolute
number of B cells per spleen was
determined by flow cytometry.
Figure 5. Virus infection interferes with peripheral tolerance induction
and activates host-specific CD81 T cells. H8 and littermate control (B6)
mice were transfused with 106 spleen cells from TCR318 mice. 3 d later,
the recipient mice were infected with 200 PFU LCMV-WE and the per-
centage of CD81 PBLs expressing the transgenic Va and Vb chains was
monitored by flow cytometric analysis (a). 8 d after challenge infection,
spleen cells from some recipient mice were tested for gp 33–specific cyto-
toxicity on EL-4 target cells in a 5-h 51Cr–release assay; spontaneous re-
lease was ,18% (b). Data from one of four similar experiments are shown.769 Ehl et al.
Role of Bone Marrow–derived Cells in the Induction of CTL-
mediated Immunopathology. To address the question of
which type of APC is involved in the observed activation
of host-specific T cells in the context of an infection, we
studied activation of CD81 T cells and immunopathology
in bone marrow chimeric mice. Infection of H8–B6 chi-
meras 3 d after transfer of 106 TCR318 cells showed that
antigen exclusively expressed on bone marrow–derived
cells is sufficient for the induction of T cell proliferation
(Fig. 7 a), the generation of host-specific cytolytic activity
(Fig. 7 b), and subsequent lethal immunopathology. It was
also sufficient for the maintenance of a high number of an-
ergic T cells in the chronic phase. Most of these features,
including acute lethal immunopathology, were also ob-
served in the B6–H8 chimeras (Fig. 7, a and b) where the
specific antigen is largely expressed on non–bone marrow–
derived cells. An exception was the maintenance of anergic
T cells in the peripheral circulation, and to a lesser extent,
in the spleen.
A Variety of Infectious and Inflammatory Stimuli Can Interfere
with Tolerance Induction. Next, we investigated whether an-
tigen-unrelated third-party infections are also able to abolish
tolerance induction and lead to activation and immunopa-
thology in this model. H8 and littermate control mice trans-
fused with 107 TCR318 spleen cells (corresponding to 106
TCR318 CD81 T cells) were challenged with a variety of
different, completely unrelated pathogens. Infections with
vesicular stomatitis virus (VSV), vaccinia virus (to a minor
Figure 6. Anergy of persisting virus-induced host-specific CD81 T cells. (a–d) Phenotypical analysis of TCR318 T cells: H8 and littermate control
(B6) mice were transfused with 106 spleen cells from TCR318 mice and infected with 200 PFU LCMV-WE 3 d later. 35 d after infection, CD81 spleen
cells of recipient mice were analyzed for expression of the transgenic Va and Vb chains (a and b). Forward light scatter of Va21Vb81CD81 TCR318 T
cells (c) and CD49d expression of Va21 CD81 T cells (d) were compared between H8 (bold lines) and littermate mice (dashed lines). (e–g) Functional anal-
ysis of TCR318 T cells. 35 d after LCMV infection, spleen cells of H8 and littermate control (B6) mice were (e) tested for gp 33–specific cytotoxicity af-
ter 5 d of restimulation on LCMV-infected macrophages in the presence of 5% Con A supernatant and ( f ) used as responder cells in a [3H]thymidine in-
corporation assay stimulated by C57BL/6 spleen cells pulsed with gp 33–41. In experiment g, the LCMV virus titer was analyzed in the indicated organs
of the recipient mice. Data from one of two to four similar experiments are shown.770 Infections Interfere with T Cell Tolerance
extent), and the intracellular bacterium Listeria monocytog-
enes all elicited a similar phenotype. This included expan-
sion of TCR318 CD81 T cells (Fig. 8 a), the generation of
gp 33–specific ex vivo cytotoxic activity (Fig. 8 c), and the
destruction of host lymphocytes (Fig. 8 d; Table 1). Inter-
estingly, injection with 500 mg Poly:IC or 10 mg LPS also
induced activation (Fig. 8 b) and immunopathology (albeit
not acutely lethal) in H8 mice (Table 1, Fig. 8 d). Both in-
fectious as well as inflammatory agents mediated their effect
without involvement of T helper cells as depletion of
CD41 T cells before infection did not change the observed
phenotype (Fig. 8 e).
Initial experiments had indicated that tenfold more (i.e.,
107) TCR318 spleen cells had to be transferred to elicit the
described phenotype with antigen-unrelated third-party
pathogens, when compared to infection with the specific
LCMV. To evaluate, whether this was due to particular
properties of LCMV infection or due to the fact that
LCMV-WE introduces the specific gp 33 epitope in a dif-
ferent context, we infected H8 mice transfused with differ-
ent amounts of TCR318 spleen cells with LCMV-WE or
with the LCMV-WE 8.7 escape mutant, which is not rec-
Figure 7. Antigen presentation by bone marrow–derived versus epi-
thelial cells for activation of host-specific CTLs. 6 wk after bone marrow
reconstitution, H8–B6 and B6–H8 bone marrow chimeras were trans-
fused with 106 spleen cells from TCR318 mice. 3 d later, the recipient
mice were infected with 200 PFU LCMV-WE and the percentage of
CD81 PBLs expressing the transgenic Va and Vb chains was monitored
by flow cytometric analysis (a). 8 d after challenge infection, spleen cells
from some recipient mice were tested for gp 33–specific cytotoxicity on
EL-4 target cells in a 5-h 51Cr–release assay; spontaneous release was
,18% (b). †Deaths.
Figure 8. Various infectious and inflammatory stimuli can interfere with tolerance induction and activate host-specific CD81 T cells. H8 (closed sym-
bols) and littermate control mice (open symbols) were transfused with 107 spleen cells from TCR318 mice and 1 d later injected with 500 mg Poly:IC, 10 mg
LPS, 2 3 106 PFU VSV-Indiana, 2 3 106 PFU vaccinia WR, 200 PFU LCMV-WE 8.7, or 200 PFU LCMV-WE. The percentage of CD81 PBLs ex-
pressing the transgenic Va and Vb chains was monitored by flow cytometry (a, b, e, and f ). 8 d after challenge infection, spleen cells from some recipient
mice were tested for gp 33–specific cytotoxicity on EL-4 target cells in a 5-h 51Cr–release assay (c). 20 d after infection, mice were killed and the absolute
number of B cells per spleen was determined by flow cytometry (d). In experiment e, mice were depleted of CD41 T cells 3 and 1 d before cell transfer.
In experiment f, the number of transferred TCR318 spleen cells was varied as indicated and mice were infected either with LCMV-WE (closed symbols) or
with LCMV-WE 8.7 (open symbols).771 Ehl et al.
ognized by the transgenic TCR. Fig. 8 f shows that 100-
fold more TCR318 CD81 T cells were required for the
mutant virus to induce measurable proliferation, indicating
that introduction of the nominal antigen in the context of
the LCMV infection strongly enhanced the response to the
transgene encoded self-antigen.
Discussion
This study shows that antigen-unrelated viral and bacte-
rial infections as well as proinflammatory agents such as
LPS and Poly:IC can influence the induction of peripheral
CD81 T cell tolerance to a widely expressed self-antigen in
vivo. Importantly, these stimuli not only prevented estab-
lishment of tolerance, but instead enhanced activation of
cytolytic CD81 effector T cells that subsequently caused
significant immunopathology.
Efficient induction of peripheral T cell tolerance after a
transient period of proliferation has been described previ-
ously in several systems using adoptive transfer of TCR
transgenic T cells into mice widely expressing their nomi-
nal antigen (9, 16–18, 33). Tolerance was found to be a
consequence of extensive proliferation and subsequent
clonal deletion, leaving a small T cell population in an an-
ergic state; T cell anergy was reversible after transfer into an
antigen-free environment (6, 34). In the present experi-
ments we found only limited activation and proliferation of
antigen-specific T cells, for which antigen expression on
bone marrow–derived cells was sufficient. This is similar to
a recent study where antigen expression in the host was
more restricted due to the use of a tissue-specific promoter
(18). Differences in the extent of T cell proliferation ob-
served in the present compared to previous studies may be
explained by differences in the TCR transgenic mice and
the use of nude (9) or scid (17) recipient mice to increase
sensitivity for the study of transferred T cells. The finding
that 12 d after transfer, TCR318 T cells could not be re-
stimulated by infection with LCMV, even after transfer
into antigen-free recipients (data not shown), suggests that
clonal deletion was mainly responsible for the tolerance in-
duction observed. A contribution of anergy can, however,
not be formally excluded. Whatever the mechanism, our
data confirm that peripheral tolerization of potentially au-
toreactive T cells involves a period of transient activation
that is usually of little functional or immunopathological
consequence.
A role for infectious agents in breaking peripheral T cell
tolerance has been documented in previous studies. Infec-
tion of mice expressing the LCMV glycoprotein in the b
cells of the endocrine pancreas with LCMV leads to activa-
tion of LCMV-specific CTLs and to the induction of dia-
betes (1, 2). Also, infection with the nematode Nipostrongulus
brasiliensis has been reported to partially reverse staphylo-
coccal enterotoxin b–induced anergy of CD41 T cells as as-
sessed by proliferation and the restoration of IL-4 production
(7, 35). While in these experiments established tolerance is
reversed, other experiments showed that some stimuli may
also abolish the induction of tolerance. It was originally re-
ported by Claman more than 30 yr ago, that bacterial LPS
can interfere with induction of B cell unresponsiveness to
g-globulin (12). Later studies showed that LPS also pre-
vents the induction CD41 T cell tolerance (36), a finding
that was recently extended to the induction of tolerance to
superantigens (15). Earlier reports had also documented
that interference with tolerance induction can lead to acti-
vation (13, 14).
This study shows that a variety of pathogens and proin-
flammatory agents such as LPS or Poly:IC can interfere
with the induction of peripheral CD81 T cell tolerance to
widely expressed antigens. The most important aspect of
our findings is that this conversion from efficient tolerance
induction to immunity towards tissue antigens can lead to
significant CD81 T cell–mediated immunopathology. Our
results emphasize the importance of the antigen-specific
component in this antihost immune reactivity. (a) In the
absence of the specific antigen, infections with VSV, Liste-
ria, or vaccinia virus or treatment with Poly:IC or LPS did
not lead to measurable LCMV-specific T cell activation
(transfer into C57BL/6 mice 1 antigen-unrelated infec-
tion), confirming that nonspecific “bystander activation” is
of low efficacy and limited biological consequence (37). (b)
In the absence of an infection, the transgene-encoded self-
antigen efficiently tolerized the antigen-reactive CD81 T
cells (transfer into H8 mice, no infection). (c) If, however,
mice were infected in the presence of the specific antigen
(transfer into H8 mice 1 antigen-unrelated or antigen-spe-
cific infection), these infections were able to activate CTLs
specific for the transgene-encoded self-antigen that caused
immunopathology. The observed pathology was only par-
tially mediated by perforin. Although activation of per-
forin-deficient gp 33–specific CD81 T cells in H8 mice did
not lead to lethality (which is presumably a consequence of
target cell destruction outside lymphoid tissue), the CD81
T cell–mediated destruction of lymphoid cells was almost
as pronounced as in mice transfused with perforin-compe-
tent cells. Whether this reflects cytotoxicity mediated by
CD95L (38, 39) or TNF-a (40, 41) remains to be tested.
Which parameters determine the conversion from toler-
ance to CTL-mediated immunopathology? Several factors
were evaluated. (a) The importance of localization and
quantity of the specific antigen (3) was well illustrated by
the comparison between the effects of infection with
LCMV-WE8.7 (carrying a mutated gp 33 epitope; refer-
ence 25) and the wild-type virus. Although these viruses do
not differ in their capacity to replicate and to induce co-
stimulatory molecules or cytokines, 50–100-fold more
TCR318 T cells had to be transferred to observe the de-
scribed phenotype after infection with the mutant com-
pared to the wild-type virus. Since wild-type virus intro-
duces the specific antigen in addition the transgene encoded
peptide mainly into APCs, this illustrates the role of speci-
ficity and indicates the importance of antigen localization
and quantity for the outcome of antigen contact of CTLs.
(b) The role of the APC type required to present the host772 Infections Interfere with T Cell Tolerance
antigen was studied in bone marrow chimera experiments,
which clearly show that in the presence of an infection, an-
tigen presentation by bone marrow–derived cells is suffi-
cient to elicit the described phenotype. The important
question of whether antigen presentation by non–bone
marrow–derived epithelial cells is sufficient to induce CTL
activation could not be conclusively addressed in this ex-
perimental model. It is well known that lethal irradiation,
as used in our study, spares some bone marrow–derived
cells, in particular dendritic cells. The reduced number of
chronically persisting antigen-specific CTLs in mice ex-
pressing the antigen mostly on non–bone marrow–derived
cells may be explained by the fact that the initiating inflam-
matory reaction is controlled faster due to the lack of sig-
nificant lymphoid pathology in these mice. (c) Previous
studies have postulated that under certain conditions CD41
T cells are important for changing CD81 T cell tolerance
into activation (11). It has also been suggested that Th1s
may promote CD81 T cell activation. In our model,
CD41 T cells were completely dispensable for the induc-
tion of CTL-mediated immunopathology. (d) The fact that
the proinflammatory substances Poly:IC or LPS could elicit
the same effect as viral or bacterial infections indicates that
a replicating pathogen is not required for antigen-specific
CTL activation under the conditions studied. The effects of
Poly:IC and LPS are severalfold. A previous study showed
that interference with superantigen-induced deletion was
not mediated by the induction of the costimulatory mole-
cule B7 on APCs (42); this remains, however, an untested
possibility. All infectious and proinflammatory agents used
have in common that they induce the secretion of various
cytokines. In this context, two recent studies have shown
that both Poly:IC and LPS can act indirectly on CD81 T
cell proliferation, presumably by stimulation of type I inter-
feron production by APCs (43). Several other redundant
cytokine pathways are conceivable including IL-1, IL-2,
IL-12, TNF, and IFN-g (15, 44). Whatever the precise
molecular mechanism, it is important to note that for a
CD81, T cell encounter of antigen is not sufficient, even if
it is presented on a “professional” APC. Under in vivo condi-
tions, the inflammatory milieu is necessary to convert this
encounter into an immunogenic, activating signal.
Some of the immunopathological consequences of infec-
tion observed in this study are reminiscent of alterations
characteristic of GVH reactions (GVHRs; reference 45). An
impact of infectious agents on the exacerbation of GVHRs
was demonstrated more than 20 yr ago (20) and enhance-
ment of donor antihost reactivity has been documented in
humans and animal models after the infection with CMV
(46, 47) and, interestingly, also after the administration of
endotoxin (48) or Poly:IC (49). Although the experimental
setup (involving the transfusion of TCR transgenic donor
spleen cells) and the fact that there was comparatively mild
pathology outside lymphoid tissue renders an analogy of
our model to this clinical condition rather limited, some of
our findings may illustrate principles relevant for activation
of host-specific T cells during GVHRs; CD81 T cell–medi-
ated antihost reactivity can be induced by a variety of bac-
terial and viral infectious agents. This does probably not in-
volve activation of specific T cells cross-reactive to tissue
antigens (50, 51) or nonspecific bystander activation (37,
43). As demonstrated in this study, activation is crucially
dependent on the presence of the specific antigen. Infec-
tions may then provide an environment that interferes with
the induction of tolerance and instead promotes activation
of cytolytic CD81 T cells to a sufficient extent to cause ex-
tensive GVHRs.
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